Emmerson (EML) announced today that its recently completed Environmental Baseline Study for the Khemisset Potash project has revealed no areas of concern regarding its scale, location, cost or profitability.

ImmuPharma is now in preparations for the Lupuzor Managed Access Program, in which 500 eligible patients in Europe will have early access to the medication, free of charge, for a minimum of two years.

Predator Oil & Gas (PRD) FOLLOW announced this week that they have received consent from Heritage Petroleum Co., Trinidad’s state-owned oil company, in record time, for their CO2 Enhanced Oil Recovery (EOR) project. The project will take place at the Inniss-Trinity oil field in Trinidad. This is set to be Predator’s first operation.

In this episode, we look at the integration and development of artificial intelligence (AI) into medical technologies, or as the sector is commonly referred to: Medtech.

SimplyBiz (SBIZ), a company providing compliance and business services to independent financial advisors, has signed a five year contract with multinational insurance company and member of the FTSE 100, Aviva. 

Live Company Group (LVCG) has launched its first BRICKLIVE show in Cologne, Germany, which will run from its debut this past Friday through June 2019. And Germany is not the only place where Live Company Group is putting down roots. 

Seeing Machines (SEE) has launched a partnership with Toll Helicopters, a specialised mission-critical helicopter provider, to introduce a unique eye tracking technology trial as part of the Toll AW-139 Full Flight Simulator in Sydney, Australia.

Indonesia focused exploration and development company, Asiamet Resources (ARS) has received key approvals to advance their 100% owned BKM copper project in Central Kalimantan, Indonesia.

Medicinal cannabis investment company Ananda Developments (ANA) FOLLOW has provided an update on its investee company, Liberty Herbal Technologies’ roll out of hapac®, a technology for inhaling medicinal cannabis, in Italy.

After the release of Shield Therapeutics (STX)'s clinical trial results sparked an over 20% increase in share price, Shield's Founder CEO Carl Sterritt stopped by our offices to tell us exactly what the study showed about their leading asset Feraccru and what impact it will have on both the company and patients.